Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update
- Opened U.S. multicenter pivotal trial in recurrent cutaneous skin cancer, which began enrolling patients in March - - Treated the first...
top of page
Treating Cancer With Precision
News
Categories
Sign up
Featured Posts
Archive
Follow Us
May 11, 2023
Alpha Tau Announces Publication: US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open
- The trial demonstrated a 100% Complete Response rate at 12 weeks post treatment and no device-related serious adverse events or...
May 4, 2023
Alpha Tau Medical to Present at Guggenheim Radiopharmaceuticals Day
JERUSALEM, May 03, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
Apr 3, 2023
Alpha Tau & JGH Announce Alpha Dart treatment of First Patient in Pancreatic Cancer Clinical Trial
-First patient treated in the feasibility and safety study of intratumoral diffusing alpha radiation emitters for the treatment of...
Mar 30, 2023
Alpha Tau Medical to Present at Jefferies Radiopharma Innovation Summit
JERUSALEM, March 30, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Mar 12, 2023
Alpha Tau Medical Confirms No Direct Exposure to Silicon Valley Bank
JERUSALEM, March 12, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer...
Mar 10, 2023
Alpha Tau Medical Announces Full Year 2022 Financial Results and Provides Corporate Update
- Opened U.S. pivotal trial in recurrent cutaneous squamous cell carcinoma, which began enrolling patients in March - - Received Health...
Mar 9, 2023
Treatment of 1st two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial
Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial -First...
Mar 5, 2023
Receipt of Increased Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval
Alpha Tau Announces Receipt of Increased Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval at its Jerusalem...
Mar 1, 2023
Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases
JERUSALEM, March 1, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
bottom of page